Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 858-864
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.858
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.858
Table 2 Prevalence of epidermal growth factor receptor mutations and comparison of responses to gefitinib and erlotinib n (%)
Ref. | No. ofpatients | EGFRmutations no | E19 Del/E21L858R | Response to prior gefitinib | Response to erlotinib | ||||||
CR | PR | SD | PD | CR | PR | SD | PD | ||||
Garfield[9] | 1 | NA | NA | 1(100) | 1(100) | ||||||
Viswanathan et al[16] | 5 | NA | NA | 4(80.0) | 1(20.0) | 5(100) | |||||
Walther et al[17] | 1 | NA | NA | 1(100) | 1(100) | ||||||
Chang et al[18] | 1 | 1 (100) | 1/0 | 1(100) | 1(100) | ||||||
Cho et al[19] | 21 | 5 (23.8) | 5/0 | 6(28.6) | 4(19.0) | 11(52.4) | 2(9.5) | 4(19.0) | 15(71.5) | ||
Gridelli et al[32] | 3 | NA | NA | 3(100) | 1(33.3) | 2(66.7) | |||||
Kim et al[33] | 1 | NA | NA | 1(100) | 1(100) | ||||||
Costa et al[23] | 181 | 17 (94.4) | 4/13 | 11(84.6) | 2(15.4) | 1(7.7) | 2(15.4) | 10(76.9) | |||
Lee et al[21] | 23 | 3 (13.0) | 3/0 | 15(65.2) | 2(8.7) | 6(26.1) | 1(4.3) | 1(4.3) | 21(91.4) | ||
Vasile et al[22] | 8 | NA | NA | 4(50.0) | 4(50.0) | 2(25.0) | 3(37.5) | 3(37.5) | |||
Wong et al[20] | 14 | 7 (50.0) | 4/3 | 9(64.3) | 5(35.7) | 5(35.7) | 9(64.3) | ||||
Wong et al[34] | 1 | 1 (100) | 1/0 | 1(100) | 1(100) | ||||||
Wu et al[35] | 1 | 1 (100) | 0/1 | 1(100) | 1(100) | ||||||
Katayama et al[36] | 7 | 6 (85.7) | 4/2 | 2(28.6) | 2(28.6) | 3(42.8) | 3(42.9) | 3(42.9) | 1(14.3) | ||
Sim et al[24] | 16 | 5 (31.3) | 2/3 | 9(56.3) | 2(12.5) | 5(31.2) | 1(6.3) | 3(18.7) | 12(75.0) | ||
Zhou et al[25] | 21 | 7 (33.3) | NA/NA | 2(9.5) | 8(38.1) | 11(52.4) | 2(9.5) | 4(19.1) | 15(71.4) | ||
Wong et al[26] | 21 | 3 (14.3) | 0/3 | 18(85.7) | 3(14.3) | 12(57.1) | 9(42.9) | ||||
Asami et al[27] | 42 | 28 (66.7) | 14/14 | 22(52.4) | 17(40.5) | 3(7.1) | 1(2.4) | 24(57.1) | 17(40.5) | ||
Hata et al[29] | 1252 | 63 (50.4) | NA/NA | 3(2.5) | 68(56.2) | 22(18.2) | 28(23.1) | 11(8.8) | 44(35.2) | 70(56.0) | |
Masuda et al[37] | 3 | 3 (100) | 2/1 | 3(100) | 3(100) | ||||||
Shoji et al[38] | 1 | 0 (0) | 0 (0) | 1(100) | 1(100) | ||||||
Song et al[39] | 20 | 5 (25.0) | 3/2 | 5(25.0) | 9(45.0) | 6(30.0) | 7(35.0) | 13(65.0) | |||
Takenaka et al[40] | 1 | 1 (100) | 1/0 | 1(100) | 1(100) | ||||||
Saito et al[41] | 21 | 12 (57.1) | 0/12 | 16(76.2) | 5(23.8) | 2(9) | 6(19) | 13(62) | |||
Tetsumoto et al[42] | 2 | 2 (100) | 1/1 | 2(100) | 2(100) | ||||||
Koyama et al[43] | 54 | 44 (81.5) | 22/22 | 4(7.4) | 32(59.3) | 13(24.0) | 5(9.3) | 0 (0) | 4(7.4) | 30(55.6) | 20(37.0) |
- Citation: Singh N, Jindal A, Behera D. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. World J Clin Oncol 2014; 5(5): 858-864
- URL: https://www.wjgnet.com/2218-4333/full/v5/i5/858.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i5.858